Skip Navigation LinksHome > May/June 2003 - Volume 19 - Issue 3 > The Cholecystokinin Antagonist Proglumide Enhances the Analg...
Text sizing:
A
A
A
Clinical Journal of Pain:
Short Report

The Cholecystokinin Antagonist Proglumide Enhances the Analgesic Effect of Dihydrocodeine

McCleane, Gary J. MD

Collapse Box

Abstract

Aim: To investigate the potential pro-analgesic effect of the non-specific CCK antagonist proglumide on the analgesia produced by dihydrocodeine.

Method: A double-blind, placebo-controlled crossover study of 30 adult subjects.

Results: Mean pain scores fell from a baseline of 8.12–7.89 during the placebo phase (N.S.) and to 6.82 during the proglumide phase (P < 0.05). Side effects were minor.

Conclusion: The CCK antagonist proglumide enhances the analgesic effect of dihydrocodeine.

We have previously shown that the cholecystokinin (CCK) antagonist proglumide enhances the analgesic effect of sustained-release morphine in subjects with chronic pain of mixed etiology. 1 This peptide, represented in the central nervous system as well as the gut, 2 has an anti-opioid effect. 3 Levels of this peptide are increased after neural injury 4,5 and with chronic opiate administration. 6 Antagonism of these elevated levels in the animal model can enhance the analgesic effect of opiates. 7,8 The aim of this study was to examine if a CCK antagonist can enhance the analgesic effect of dihydrocodeine in human subjects.

© 2003 Lippincott Williams & Wilkins, Inc.

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.